Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 in Asymptomatic mCRPC Post-Abiraterone/Enzalutamide
NCT03002220Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Dec 2016
- Primary completion
- May 2020
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by MEDSIR. Started Dec 2016; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03002220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002220.